New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
07:40 EDTPOZN, SNYPOZEN says reduced R&D staff, other costs as part of controlling expenses
POZEN (POZN) said, "For FY14, the company’s areas of strategic focus are obtaining FDA approval for PA8140/PA32540, transitioning all licensed know-how relating to PA8140/PA32540 in the U.S. and fulfilling all contractual obligations to Sanofi (SNY) U.S., completing study PA10040-102, an additional Phase 1 pharmacodynamics study, preparing the regulatory filing document for PA product candidates in the European Union, finding partners for the PA asset in ex-U.S. territories, and controlling expenses. As part of controlling expenses, we have reduced our R&D staff and other costs and in the future will continue to reduce staff not required to support our ongoing business activities. Our board of directors and management team continue to explore potential ways to return value to our shareholders, including future cash distributions when we accumulate surplus cash as a result of receiving milestones and royalties from our commercial partners."
News For POZN;SNY From The Last 14 Days
Check below for free stories on POZN;SNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
09:02 EDTSNYSanofi, InnerWorkings sign global marketing partnership
Subscribe for More Information
July 21, 2014
07:11 EDTSNYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
July 16, 2014
09:03 EDTSNYSanofi held talks on mature drugs with Abbott, Mylan, PE firms, Reuters says
Sanofi (SNY) has shopped an $8.5B portfolio of mature drugs to Abbott (ABT), Mylan (MYL) and private equity firms, according to Reuters, citing an internal company document circulated by the CGT union. Sanofi is considering whether to sell, carve out or create a joint venture for the portfolio of about 200 drugs, but a Sanofi spokesman said no decision has yet been made, the report noted. Reference Link
07:31 EDTPOZNPOZEN announces FDA appectance of PA8140/PA32540 NDA refiling
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use